Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
30
ACLX Quote, Financials, Valuation and Earnings
Last price:
$52.74
Seasonality move
:
29.76%
Day range:
$49.00 - $64.71
52-week range:
$47.88 - $107.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.20x
P/B ratio:
6.38x
Volume:
3M
Avg. volume:
693.4K
1-year change:
0.25%
Market cap:
$2.9B
Revenue:
$107.9M
EPS (TTM):
-$2.00
Analysts' Opinion
-
Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $115.40, Arcellx has an estimated upside of 118.56% from its current price of $52.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $104.00 representing 100% downside risk from its current price of $52.80.
Fair Value
-
According to the consensus of 12 analysts, Arcellx has 118.56% upside to fair value with a price target of $115.40 per share.
ACLX vs. S&P 500
-
Over the past 5 trading days, Arcellx has underperformed the S&P 500 by -18.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arcellx does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcellx revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Arcellx reported revenues of $15.3M.
Earnings Growth
-
Arcellx has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arcellx reported earnings per share of -$0.87.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
26.20x
EV / EBIT:
--
EV / Revenue:
21.44x
PEG ratio (5yr expected):
-0.73x
EV / Free cash flow:
-23.88x
Price / Operating cash flow:
895.28x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-14.07%
Net Income Margin (TTM):
-99.46%
Return On Equity:
-22.3%
Return On Invested Capital:
-22.3%
Operating Margin:
-348.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $110.3M | $107.9M | $63.1M | $15.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$191.3M | -$89.9M | -$137.6M | $15M | -$53.2M | |
| EBITDA | -$185.6M | -$64.1M | -$99.1M | $22.2M | -$43.8M | |
| Diluted EPS | -$4.97 | -$1.47 | -$2.00 | $0.42 | -$0.87 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.4M | $112.8M | $266.9M | $716.4M | $599.3M | |
| Total Assets | $57.7M | $128.8M | $313.8M | $825.1M | $711.3M | |
| Current Liabilities | $5.3M | $14.8M | $56.7M | $118.2M | $125.4M | |
| Total Liabilities | $121.4M | $250.3M | $108.9M | $339.8M | $256.5M | |
| Total Equity | -$63.7M | -$121.5M | $205M | $485.4M | $454.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$99.3M | $207.6M | -$83.5M | $58.2M | -$46M | |
| Cash From Investing | -$117.7M | -$154.5M | -$183M | $21M | -$4.1M | |
| Cash From Financing | $252.6M | $279.2M | -$24.1M | $188.6M | -$6M | |
| Free Cash Flow | -$101.6M | $186.1M | -$96.9M | $53M | -$47.5M | |
ACLX
Sector
Market Cap
$2.9B
$35.1M
Price % of 52-Week High
49.18%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
0.25%
-40.62%
Beta (5-Year)
--
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$63.31
200-day SMA
Sell
Level
$73.14
Bollinger Bands (100)
Sell
Level
61.14 - 74.8
Chaikin Money Flow
Buy
Level
13.8M
20-day SMA
Sell
Level
$61.56
Relative Strength Index (RSI14)
Sell
Level
31.10
ADX Line
Sell
Level
19.5
Williams %R
Neutral
Level
-79.3028
50-day SMA
Sell
Level
$65.01
MACD (12, 26)
Sell
Level
-0.74
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.2282)
Sell
CA Score
(Annual)
Level (-0.5086)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.108)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Stock Forecast FAQ
In the current month, ACLX has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACLX average analyst price target in the past 3 months is $115.40.
-
Where Will Arcellx Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcellx share price will rise to $115.40 per share over the next 12 months.
-
What Do Analysts Say About Arcellx?
Analysts are divided on their view about Arcellx share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcellx is a Sell and believe this share price will drop from its current level to $104.00.
-
What Is Arcellx's Price Target?
The price target for Arcellx over the next 1-year time period is forecast to be $115.40 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACLX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcellx is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACLX?
You can purchase shares of Arcellx via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcellx shares.
-
What Is The Arcellx Share Price Today?
Arcellx was last trading at $52.74 per share. This represents the most recent stock quote for Arcellx. Yesterday, Arcellx closed at $52.80 per share.
-
How To Buy Arcellx Stock Online?
In order to purchase Arcellx stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is up 34.66% over the past day.
Buy
63
SKX alert for May 7
Skechers USA [SKX] is down 0.07% over the past day.
